1-20 of 33
Vivek Subbiah
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Predicting the Abscopal Phenomenon—Reply

Blessie Elizabeth Nelson, Vivek Subbiah
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (2): 250.
https://doi.org/10.1158/1535-7163.MCT-23-0581
Published: 01 February 2024
View article titled, Predicting the Abscopal Phenomenon—Reply
Open the PDF for Predicting the Abscopal Phenomenon—Reply in another window
Journal Articles

Abstract B043: Preliminary results from a phase I/II study evaluating the safety, tolerability, and efficacy of EP0031, a next generation selective RET inhibitor, in patients with advanced RET-altered malignancies

Elena Garralda, Alonso Guzman, Pilar Garrido, Andrew G Gianoukakis, Matthew Taylor, Sarina Piha-Paul, Matthew G Krebs, Antoine Italiano, Liz Clark, Geoff Fisher, Tobi Arkenau, Vivek Subbiah
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): B043.
https://doi.org/10.1158/1535-7163.TARG-23-B043
Published: 01 December 2023
View article titled, Abstract B043: Preliminary results from a phase I/II study evaluating the safety, tolerability, and efficacy of EP0031, a next generation selective RET inhibitor, in patients with advanced RET-altered malignancies
Journal Articles

Abstract C031: A randomized Phase 1b study of IGM-8444 in combination with FOLFIRI + bevacizumab compared to FOLFIRI + bevacizumab alone in second line metastatic colorectal cancer

Susanna Ulahannan, Meredith Pelster, Patricia LoRusso, Gerald Falchook, Judy Wang, Minal Barve, Jaspreet Grewal, Warren Chow, Jason Henry, Michael Cecchini, Vivek Subbiah, Maya Leabman, Genevive Hernandez, Yao Li, Angus Sinclair, Beatrice Wang, Maya Kotturi, Eric Humke, Sean Ahern, Leslie Ennis, Melaine Caruano, Sapeck Agrawal
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): C031.
https://doi.org/10.1158/1535-7163.TARG-23-C031
Published: 01 December 2023
View article titled, Abstract C031: A randomized Phase 1b study of IGM-8444 in combination with FOLFIRI + bevacizumab compared to FOLFIRI + bevacizumab alone in second line metastatic colorectal cancer
Journal Articles

Abstract A137: Pharmacokinetics and pharmacodynamics of IGM-8444, a first-in-class engineered pentameric DR5-targeting agonist IgM monoclonal antibody, in patients with R/R and newly diagnosed cancers

Genevive Hernandez, Sanela Bilic, Yinghui Guan, John So, Sabya Bhattacharya, Beatrice Wang, Maya Kotturi, Miho Oyasu, Melanie Desbois, Yuan Cao, Eric Humke, Sean Ahern, Angus Sinclair, Susanna Ulahannan, Vivek Subbiah, Merideth Pelster, Patricia Lorusso, Gerald Falchook, Judy Wang, Minal Barve, Jaspreet Grewal, Warren Chow, Jason Henry, Michael Cecchini, Chris Takimoto, Maya Leabman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): A137.
https://doi.org/10.1158/1535-7163.TARG-23-A137
Published: 01 December 2023
View article titled, Abstract A137: Pharmacokinetics and pharmacodynamics of IGM-8444, a first-in-class engineered pentameric DR5-targeting agonist IgM monoclonal antibody, in patients with R/R and newly diagnosed cancers
Journal Articles

Abstract IA006: Clinical activity of lirafugratinib (RLY-4008), a highly selective FGFR2 inhibitor, in patients with advanced FGFR2-altered solid tumors: The ReFocus study

Alison M Schram, Vivek Subbiah, Chih-Yi (Andy) Liao, Victor Moreno, Roda Desamparados, Mariano Ponz-Sarvise, Efrat Dotan, Philippe Alexandre Cassier, Irene Moreno, Andreas Varkaris, Richard D Kim, Elena Garralda, Frans Opdam, David Tai, Antoine Italiano, Do-Youn Oh, Lipika Goyal, Elisa Fontana, Jia Liu, Myrto Boukovala, Francois Ghiringelli, Mitesh J Borad, Hani Babiker, Zhaohui Jin, Michael Millward, Jeffrey Yachnin, Suneel Deepak Kamath, Jermaine M. Coward, Changhoon Yoo, Robin Kate Kelley, Vaibhav Sahai, John Bridgewater, Christoph Springfield, Vaia Florou, Anthony El-Khoueiry, Ferry Eskens, Bruce Lin, Scott Paulson, Giuseppe Curigliano, Meredith Murphy, Alicia Deary, Fabien Ricard, Kai Yu Jen, Florence (Tianhui) Ramirez, Rick E. Blakesley, Oleg Schmidt-Kittler, Brenton G. Mar, Joon Oh Park, Antoine Hollebecque
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): IA006.
https://doi.org/10.1158/1535-7163.TARG-23-IA006
Published: 01 December 2023
View article titled, Abstract IA006: Clinical activity of lirafugratinib (RLY-4008), a highly selective FGFR2 inhibitor, in patients with advanced FGFR2-altered solid tumors: The ReFocus study
Journal Articles

Abstract C067: Patient-reported baseline symptomatic adverse events in early-phase trials of combination treatments with immune checkpoint blockade, and their association with concurrent global health status, health utilities and clinical factors

Goldy C. George, Sarina A Piha-Paul, Siqing Fu, Ecaterina Dumbrava, Vivek Subbiah, Apostolia Tsimberidou, George Blumenschein, Shubham Pant, Grace Appleton, Laila Noor, Jordi Rodon Ahnert, Timothy Yap, Funda Meric-Bernstam, Charles Cleeland, Tito Mendoza, David S Hong
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): C067.
https://doi.org/10.1158/1535-7163.TARG-23-C067
Published: 01 December 2023
View article titled, Abstract C067: Patient-reported baseline symptomatic adverse events in early-phase trials of combination treatments with immune checkpoint blockade, and their association with concurrent global health status, health utilities and clinical factors
Journal Articles

Predicting the Abscopal Effect: Associated Tumor Histologic Subtypes and Biomarkers

Blessie Elizabeth Nelson, Jacob J. Adashek, Aakash Akshay Sheth, Vivek Subbiah
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (6): 706–716.
https://doi.org/10.1158/1535-7163.MCT-22-0516
Published: 01 June 2023
View article titled, Predicting the Abscopal Effect: Associated Tumor Histologic Subtypes and Biomarkers
Open the PDF for Predicting the Abscopal Effect: Associated Tumor Histologic Subtypes and Biomarkers in another window
Journal Articles

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors

Jacob J. Adashek, Arjun K. Menta, Neha K. Reddy, Aakash P. Desai, Jason Roszik, Vivek Subbiah
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (6): 871–878.
https://doi.org/10.1158/1535-7163.MCT-21-0950
Published: 01 June 2022
View article titled, Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
Open the PDF for Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors in another window
Includes: Supplementary data
Journal Articles

A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody–Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors

Matteo Duca, Darren Wan-Teck Lim, Vivek Subbiah, Shunji Takahashi, John Sarantopoulos, Andrea Varga, Joseph A. D'Alessio, Tinya Abrams, Qing Sheng, Eugene Youchin Tan, Maria Santos Rosa, Juan Gonzalez-Maffe, Janna Sand-Dejmek, Claire Fabre, Miguel Martin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (4): 625–634.
https://doi.org/10.1158/1535-7163.MCT-21-0652
Published: 01 April 2022
View article titled, A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody–Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors
Open the PDF for A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody–Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors in another window
Journal Articles

Abstract P035: A phase 1 pharmacokinetic trial of single agent trametinib a MEK inhibitor in advanced cancer patients with hepatic dysfunction: An NCI Organ Dysfunction Working Group (ODWG) study (NCI 9591)

Pei Jye Voon, Eric X. Chen, Helen X. Chen, Albert C. Lockhart, Solmaz Sahebjam, Karen Kelly, Ulka N. Vaishampayan, Vivek Subbiah, Albiruni R. Razak, Daniel J. Renouf, Sebastien J. Hotte, Arti Singh, Philippe L. Bedard, Aaron R. Hansen, Ivy S. Percy, Lisa Wang, Lee-Anne Stayner, Lillian L. Siu, Anna Spreafico
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P035.
https://doi.org/10.1158/1535-7163.TARG-21-P035
Published: 01 December 2021
View article titled, Abstract P035: A phase 1 pharmacokinetic trial of single agent trametinib a MEK inhibitor in advanced cancer patients with hepatic dysfunction: An NCI Organ Dysfunction Working Group (ODWG) study (NCI 9591)
Journal Articles

Abstract P02-02: First results of RLY-4008, a potent and highly selective FGFR2 inhibitor in a first-in-human study in patients with FGFR2-altered cholangiocarcinoma and multiple solid tumors

Lipika Goyal, Mitesh Borad, Vivek Subbiah, Amit Mahipal, Suneel Kamath, Kabir Mody, Robin Katie Kelley, Richard Kim, Vaibhav Sahai, Anthony El-Khoueiry, Efrat Dotan, Oleg Schmidt-Kittler, Jinshan Shen, Kai Yu Jen, Alicia Deary, Wei Guo, Mahesh Padval, Cori Ann J. Sherwin, Charles Ferte, Beni Wolf, Alison M. Schram
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P02-02.
https://doi.org/10.1158/1535-7163.TARG-21-P02-02
Published: 01 December 2021
View article titled, Abstract P02-02: First results of RLY-4008, a potent and highly selective FGFR2 inhibitor in a first-in-human study in patients with FGFR2-altered cholangiocarcinoma and multiple solid tumors
Journal Articles

Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers

Jacob J. Adashek, Aakash P. Desai, Alexander Y. Andreev-Drakhlin, Jason Roszik, Gilbert J. Cote, Vivek Subbiah
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (10): 1769–1776.
https://doi.org/10.1158/1535-7163.MCT-21-0329
Published: 01 October 2021
View article titled, Hallmarks of RET and Co-occuring Genomic Alterations in <em>RET</em>-aberrant Cancers
Open the PDF for Hallmarks of RET and Co-occuring Genomic Alterations in <em>RET</em>-aberrant Cancers in another window
Journal Articles

Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies

Roman Groisberg, Jason Roszik, Anthony P. Conley, Alexander J. Lazar, Daniella E. Portal, David S. Hong, Aung Naing, Cynthia E. Herzog, Neeta Somaiah, Maria A. Zarzour, Shreyaskumar Patel, Robert E. Brown, Vivek Subbiah
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2020) 19 (5): 1165–1172.
https://doi.org/10.1158/1535-7163.MCT-19-0579
Published: 04 May 2020
View article titled, Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies
Open the PDF for Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies in another window
Journal Articles

Abstract A078: FIGHT-101: A phase 1/2 study of pemigatinib, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, as monotherapy and as combination therapy in patients with advanced malignancies

Vivek Subbiah, Minal Barve, Nicholas O. Iannotti, Martin Gutierrez, David C. Smith, Sameek Roychowdhury, Kyriakos P. Papadopoulos, Niharika Mettu, William J. Edenfield, Daniel Morgensztern, Luis Féliz, Christine Lihou, Huiling Zhen, Mansoor Saleh
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): A078.
https://doi.org/10.1158/1535-7163.TARG-19-A078
Published: 01 December 2019
View article titled, Abstract A078: FIGHT-101: A phase 1/2 study of pemigatinib, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, as monotherapy and as combination therapy in patients with advanced malignancies
Journal Articles

Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers

Roman Groisberg, David S. Hong, Jason Roszik, Filip Janku, Apostolia M. Tsimberidou, Milind Javle, Funda Meric-Bernstam, Vivek Subbiah
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2018) 17 (7): 1595–1601.
https://doi.org/10.1158/1535-7163.MCT-17-1107
Published: 01 July 2018
View article titled, Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers
Open the PDF for Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers in another window
Journal Articles

Phase I Dose-Escalation Study of Anti–CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers

Divya Sakamuri, Isabella C. Glitza, Sonia L. Betancourt Cuellar, Vivek Subbiah, Siqing Fu, Apostolia M. Tsimberidou, Jennifer J. Wheler, David S. Hong, Aung Naing, Gerald S. Falchook, Michelle A. Fanale, Maria E. Cabanillas, Filip Janku
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (3): 671–676.
https://doi.org/10.1158/1535-7163.MCT-17-0673
Published: 28 February 2018
View article titled, Phase I Dose-Escalation Study of Anti–CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers
Open the PDF for Phase I Dose-Escalation Study of Anti–CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers in another window
Journal Articles

Abstract A096: Phase II study of the PARP inhibitor talazoparib in advanced cancer patients with somatic alterations in BRCA1/2, mutations/deletions in PTEN or PTEN loss, aberrations in other BRCA pathway genes, and germline mutations in BRCA1/2 (not breast or ovarian cancer)

Sarina A. Piha-Paul, Wendy Wen Xiong, Tyler Moss, Rosa M. Mostorino, Shelby Sedelmeier, Kenneth Hess, Siqing Fu, David Hong, Filip Janku, Daniel Karp, Aung Naing, Shubham Pant, Jordi Rodon, Vivek Subbiah, A M. Tsimberidou, Timothy Yap, Milind Javle, Coya Tapia, Kenna R. Shaw, Karina Eterovic, Gordon B. Mills, Funda Meric-Bernstam
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A096.
https://doi.org/10.1158/1535-7163.TARG-17-A096
Published: 01 January 2018
View article titled, Abstract A096: Phase II study of the PARP inhibitor talazoparib in advanced cancer patients with somatic alterations in <em>BRCA1/2</em>, mutations/deletions in <em>PTEN</em> or PTEN loss, aberrations in other <em>BRCA</em> pathway genes, and germline mutations in <em>BRCA1/2</em> (not breast or ovarian cancer)
Journal Articles

Abstract A098: Preliminary results from a phase 1/2 study of INCB054828, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced malignancies

Mansoor Saleh, Martin Gutierrez, Vivek Subbiah, David C. Smith, Luis Féliz, Huiling Zhen, Tao Ji, John Nemunaitis
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A098.
https://doi.org/10.1158/1535-7163.TARG-17-A098
Published: 01 January 2018
View article titled, Abstract A098: Preliminary results from a phase 1/2 study of INCB054828, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced malignancies
Journal Articles

Abstract A167: Targeting HER2 (ERBB2) amplification identified by next-generation sequencing (NGS) in patients with advanced or metastatic solid tumors

Ecaterina Ileana Dumbrava, Kavitha Balaji, Kanwal Raghav, Milind Javle, Mariela Blum-Murphy, Blessy Sajan, Scott Kopetz, Russell Broaddus, Mark Routbort, Shubham Pant, Apostolia Tsimberidou, Vivek Subbiah, David S. Hong, Jordi Rodon Ahnert, Kenna Shaw, Sarina Piha-Paul, Funda Meric-Bernstam
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A167.
https://doi.org/10.1158/1535-7163.TARG-17-A167
Published: 01 January 2018
View article titled, Abstract A167: Targeting HER2 (ERBB2) amplification identified by next-generation sequencing (NGS) in patients with advanced or metastatic solid tumors
Journal Articles

Abstract A199: Association of immune checkpoint inhibitor dose and survival in phase I clinical trials: is it time to redefine the recommended phase II dose

Shiraj Sen, David S. Hong, Kenneth Hess, Funda Meric-Bernstam, Vivek Subbiah
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A199.
https://doi.org/10.1158/1535-7163.TARG-17-A199
Published: 01 January 2018
View article titled, Abstract A199: Association of immune checkpoint inhibitor dose and survival in phase I clinical trials: is it time to redefine the recommended phase II dose